A preclinical study published in 2023 investigated the effects of targeting CDK4/6, MEK and PD‐L1 in MPNST and found that CDK4/6 and MEK inhibitors induced an immune response and anti‐tumor activity, which in turn enhanced the effect of anti‐PD‐L1 immune checkpoint blockade in MPNST [27]. Here, CDK4 is linked to malignant peripheral nerve sheath tumor.